



UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 18 2009

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450
www.uspto.gov

Jeffrey P. Kushan
Sidley Austin, LLP
1501 K Street, N.W.
Washington, DC 20005

Re: Patent Term Extension
Application for
U.S. Patent No. 6,884,879

WITHDRAWAL OF APPLICATION FOR PATENT TERM EXTENSION

This is in response to the "Election Under 37 C.F.R. § 1.785(b)" filed April 24, 2009, of the application for patent term extension for U.S. Patent No. 6,407,213, (LUCENTIS® (ranibizumab)). The present application for patent term extension for U.S. Patent No. 6,884,879 is withdrawn in favor of the elected patent, U.S. Patent No. 6,407,213.

The present application is hereby withdrawn from consideration and dismissed.

Any correspondence with respect to this matter should be addressed as follows:

By mail: Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Telephone inquiries related to this determination should be directed to the undersigned at (571) 272-7755. E-mail inquiries should be directed to mary.till@uspto.gov.

Mary C. Till
Legal Advisor
Office of Patent Legal Administration
Office of the Deputy Commissioner
for Patent Examination Policy

cc: Office of Regulatory Policy
Food and Drug Administration
10903 New Hampshire Ave., Bldg. 51, Rm. 6222
Silver Spring, MD 20993-0002

RE: LUCENTIS® (ranibizumab)
FDA Docket No.: FDA-2007-E-0165

Attention: Beverly Friedman